



DEPARTMENT OF DEFENSE
ARMED FORCES EPIDEMIOLOGICAL BOARD
5109 LEESBURG PIKE
FALLS CHURCH, VA 22041-3258



REPLY TO
ATTENTION OF

AFEB (15-1a) 93-8

22 June 1993

MEMORANDUM FOR THE ASSISTANT SECRETARY OF DEFENSE (HEALTH AFFAIRS)
THE SURGEON GENERAL, DEPARTMENT OF THE ARMY
THE SURGEON GENERAL, DEPARTMENT OF THE NAVY
THE SURGEON GENERAL, DEPARTMENT OF THE AIR FORCE


SUBJECT: Tick-Borne Encephalitis (TBE) Vaccine


1. The U. S. Army Medical Research Institute of Infectious Diseases (USAMRIID) holds an Investigational New Drug (IND) Permit for the TBE vaccine manufactured by the Austrian firm, Immuno AG. The vaccine has been used extensively in Austria and has been used by the U. S. Army Medical Department for several years to immunize at-risk soldiers and Department of Defense civilians on weapons inspection teams traveling to the former USSR.

2. Based on efficacy data presented at the 25 February 1993 and 3-4 June 1993 meetings of the AFEB:

**THE BOARD SUPPORTS THE USE OF THE TBE VACCINE
UNDER IND PROTOCOL WITH INFORMED CONSENT FOR
USE IN MILITARY PERSONNEL/UNITS AND CIVILIAN
BENEFICIARIES DETERMINED BY THE SERVICES TO
HAVE SIGNIFICANT POTENTIAL FOR EXPOSURE TO
TBE IN ENDEMIC AREAS.**

FOR THE ARMED FORCES EPIDEMIOLOGICAL BOARD:


WALTER R. DOWDLE, Ph.D.
President, AFEB


MICHAEL R. PETERSON, DVM, MPH, DrPH
Colonel, USAF, BSC
Executive Secretary

Copies Furnished:

Board Members

Ch, HQ, USAF, SGP

Ch, Prev Med Div, OTSG-DA

Ch, Prev Med Div, OTSG-DAF

Dir. Occup Hlth & Prev Med Div, BUMED-DN

DASD (PA&QA)

Cmdr, U. S. Army Med R&D Cmd

Dir, Prof Svcs, OTSG-DA

Dir, Env & Life Sci, OUSDA, ATTN: Dr. J. Osterman

Cmdr, HSHA-Z, Brooks AFB